PREVAIL IV: A Randomized, Double-Blind, 2-Phase, Phase 2 Trial of Remdesivir vs Placebo for Reduction of Ebola Virus RNA in the Semen of Male Survivors.
Ebola survivors
Ebola virus disease
controlled clinical trial
post-Ebola syndrome
remdesivir
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
16 11 2021
16 11 2021
Historique:
received:
05
10
2020
pubmed:
13
3
2021
medline:
23
11
2021
entrez:
12
3
2021
Statut:
ppublish
Résumé
Ebola virus RNA persists in the semen of male Ebola survivors for months to years after the acute infection, and male-to-female sexual transmission of the virus is well documented. We investigated whether remdesivir can safely reduce persistence of seminal Ebola virus RNA. We recruited men with persistent seminal Ebola RNA in Liberia and Guinea. Participants were randomized 1:1 to receive intravenous remdesivir (GS-5734; Gilead Sciences) or matching placebo administered once daily by intravenous infusion over 1 hour on 5 consecutive days. Stratification was by country and number of positive (1 or 2) preenrollment semen tests. We evaluated the difference in mean assay negativity rate (ANR), that is, the proportion of negative tests for each participant in each group in the treatment (days 1-28) and follow-up (months 2-6) phases on an intention-to-treat basis. We enrolled 38 men from July 2016 through June 2018. The mean treatment phase ANRs were 85% (standard deviation [SD] = 24%) and 76% (SD = 30%) in the remdesivir and placebo arms, respectively (P = .270). The mean follow-up phase ANRs were 96% (SD = 10%) and 81% (SD = 29%) in the remdesivir and placebo arms, respectively (P = .041). The 5-day remdesivir regimen was well tolerated with no safety concerns. In this small trial, remdesivir 100 mg/day for 5 days safely reduced the presence of Ebola virus RNA in the semen of Ebola survivors 2 to 6 months after administration. A larger follow-up study is necessary to confirm results. Clinical Trials Registration . NCT02818582.
Sections du résumé
BACKGROUND
Ebola virus RNA persists in the semen of male Ebola survivors for months to years after the acute infection, and male-to-female sexual transmission of the virus is well documented. We investigated whether remdesivir can safely reduce persistence of seminal Ebola virus RNA.
METHODS
We recruited men with persistent seminal Ebola RNA in Liberia and Guinea. Participants were randomized 1:1 to receive intravenous remdesivir (GS-5734; Gilead Sciences) or matching placebo administered once daily by intravenous infusion over 1 hour on 5 consecutive days. Stratification was by country and number of positive (1 or 2) preenrollment semen tests. We evaluated the difference in mean assay negativity rate (ANR), that is, the proportion of negative tests for each participant in each group in the treatment (days 1-28) and follow-up (months 2-6) phases on an intention-to-treat basis.
RESULTS
We enrolled 38 men from July 2016 through June 2018. The mean treatment phase ANRs were 85% (standard deviation [SD] = 24%) and 76% (SD = 30%) in the remdesivir and placebo arms, respectively (P = .270). The mean follow-up phase ANRs were 96% (SD = 10%) and 81% (SD = 29%) in the remdesivir and placebo arms, respectively (P = .041). The 5-day remdesivir regimen was well tolerated with no safety concerns.
CONCLUSIONS
In this small trial, remdesivir 100 mg/day for 5 days safely reduced the presence of Ebola virus RNA in the semen of Ebola survivors 2 to 6 months after administration. A larger follow-up study is necessary to confirm results. Clinical Trials Registration . NCT02818582.
Identifiants
pubmed: 33709142
pii: 6168541
doi: 10.1093/cid/ciab215
pmc: PMC8824795
doi:
Substances chimiques
remdesivir
3QKI37EEHE
Adenosine Monophosphate
415SHH325A
RNA
63231-63-0
Alanine
OF5P57N2ZX
Banques de données
ClinicalTrials.gov
['NCT02818582']
Types de publication
Clinical Trial, Phase II
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1849-1856Subventions
Organisme : National Institutes of Health and the Liberian Ministry of Health
Commentaires et corrections
Type : CommentIn
Informations de copyright
Published by Oxford University Press for the Infectious Diseases Society of America 2021.
Références
Lancet Infect Dis. 2019 Mar;19(3):308-316
pubmed: 30765243
N Engl J Med. 2015 Jun 18;372(25):2423-7
pubmed: 25950269
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Lancet. 2016 Jul 30;388(10043):498-503
pubmed: 27209148
Lancet Infect Dis. 2018 Sep;18(9):1015-1024
pubmed: 30049622
N Engl J Med. 2019 Dec 12;381(24):2293-2303
pubmed: 31774950
J Infect Dis. 2016 Apr 15;213(8):1237-9
pubmed: 26374912
N Engl J Med. 2017 Oct 12;377(15):1428-1437
pubmed: 26465681
Nature. 2016 Mar 17;531(7594):381-5
pubmed: 26934220
N Engl J Med. 2019 Mar 7;380(10):924-934
pubmed: 30855742
Lancet Infect Dis. 2017 May;17(5):545-552
pubmed: 28094208
Sci Rep. 2019 Feb 7;9(1):1653
pubmed: 30733561